Know What's Happening in Industry

Denifanstat Posts Positive Phase III Results for Acne Treatment

Ascletis Pharma announced that its oral fatty‑acid‑synthase inhibitor denifanstat (ASC40) achieved positive Phase III results in moderate‑to‑severe acne vulgaris. In a 480‑patient double‑blind trial, 33% of participants reached clear or almost‑clear skin versus 15% on placebo, and an open‑label safety study of 240 patients showed no grade 3‑4 adverse events. The China NMPA has accepted Ascletis’s New Drug Application, positioning the drug for imminent regulatory review. Sagimet Biosciences, the global licensor, is extending development beyond Greater China.